Table 1. Baseline patient characteristics by VeriStrat classification.
| Overall | VeriStrat Good (N=50) | VeriStrat Poor (N=26) | P-value | |
|---|---|---|---|---|
|
Age (years) | ||||
| Range | 44–80 | 44–76 | 46–80 | 0.2639 |
| Median | 66 | 66 | 66 | |
|
Gender | ||||
| Male, N (%) | 51 (67) | 34 (68) | 17 (65) | 1 |
| Female, N (%) | 25 (33) | 16 (32) | 9 (35) | |
|
Histology | ||||
| Adenocarcinoma, N (%) | 75 (99) | 49 (98) | 26 (100) | 1 |
| NOS, N (%) | 1 (1) | 1 (2) | 0 | |
|
Stage | ||||
| IV | 76 (100) | 50 (100) | 26 (100) | — |
|
Smoking | ||||
| Never smoker, N (%) | 7 (9) | 4 (8) | 3 (11) | 0.8219 |
| Former smoker, N (%) | 30 (40) | 21 (42) | 9 (35) | |
| Smoker, N (%) | 39 (51) | 25 (50) | 14 (54) | |
|
Prior radiation therapy | ||||
| No, N (%) | 72 (95) | 48 (96) | 24 (92) | 0.6028 |
| Yes, N (%) | 4 (5) | 2 (4) | 2 (8) | |
|
Prior surgery | ||||
| No, N (%) | 70 (92) | 45 (90) | 25 (96) | 0.6576 |
| Yes, N (%) | 6 (8) | 5 (10) | 1 (4) | |
|
Maintenance | ||||
| No, N (%) | 44 (58) | 23 (48) | 21 (81) | 0.0065 |
| Yes, N (%) | 32 (42) | 27 (52) | 5 (19) | |
|
ECOG PS | ||||
| 0, N (%) | 20 (26) | 15 (30.00) | 5 (19) | 0.4144 |
| 1, N (%) | 54 (71) | 33 (66.00) | 21 (81) | |
| 2, N (%) | 2 (3) | 2 (4.00) | 0 | |
|
Chemotherapy type | ||||
| Carbo/Pem, N (%) | 43 (57) | 28 (56.00) | 15 (58) | 1 |
| Cis/Pem, N (%) | 33 (43) | 22 (44.00) | 11 (42) | |
|
KRAS status | ||||
| Wild type, N (%) | 31 (41) | 24 (48.00) | 7 (27) | 0.1766 |
| Mutation, N (%) | 29 (38) | 16 (32.00) | 13 (50) | |
| Unknown, N (%) | 16 (21) | 10 (20.00) | 6 (23) | |
|
EGFR status | ||||
| Wild type, N (%) | 67 (88) | 43 (86.00) | 24 (92) | 0.855 |
| Mutant, N (%) | 2 (3) | 2 (4.00) | 0 | |
| Unknown, N (%) | 7 (9) | 5 (10.00) | 2 (8) | |
|
ALK translocation | ||||
| Negative, N (%) | 54 (71) | 37 (74.00) | 17 (65) | 0.6193 |
| Positive, N (%) | 1 (1) | 1 (2.00) | 0 | |
| Unknown, N (%) | 21 (28) | 12 (24.00) | 9 (35) | |
Abbreviations: ALK=anaplastic lymphoma kinase; Carbo=carboplatin; Cis=cisplatin; ECOG=Eastern Cooperative Oncology Group; EFGR=epidermal growth factor receptor; KRAS=Kirsten rat sarcoma viral oncogene; NOS=not otherwise specified; Pem=pemetrexed; PS=performance status.